Treatment of Osteoporosis, with a Focus on 2 Monoclonal Antibodies

被引：16

作者：

Chang, Biao ^{[1
]}

Quan, Qi ^{[2
]}

Li, Yunqi ^{[1
]}

Qiu, Haixia ^{[1
]}

Peng, Jiang ^{[2
]}

Gu, Ying ^{[1
]}

机构：

[1] Chinese Peoples Liberat Army Gen Hosp, Dept Laser Med, Beijing, Peoples R China

[2] Chinese Peoples Liberat Army Gen Hosp, Dept Orthoped, Beijing, Peoples R China

来源：

MEDICAL SCIENCE MONITOR | 2018年 / 24卷

基金：

国家重点研发计划;

关键词：

Osteoporosis; Therapeutic Uses; Wnt Signaling Pathway; BONE-MINERAL DENSITY; INTRAVENOUS ZOLEDRONIC ACID; ALENDRONATE; 70; MG; POSTMENOPAUSAL WOMEN; PARATHYROID-HORMONE; FRACTURE RISK; OSTEOCLAST DIFFERENTIATION; OSTEOPROTEGERIN LIGAND; TERIPARATIDE TREATMENT; SCLEROSTIN ANTIBODY;

D O I：

10.12659/MSM.912309

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Osteoporosis is a common skeletal disease characterized by bone loss and subsequent increased risk of fragility fractures. Recent advances in our mechanistic understanding of molecular communications among osteoblasts, osteoclasts, and osteocytes give insight into the important roles of the canonical Wnt/beta-catenin pathway and the RANK/RANKL/OPG pathway in the process of bone remodeling. Due to the translation of the canonical Wnt/beta-catenin pathway and the RANK/RANKL/OPG pathway in the regulation of osteoblasts and osteoclasts, new targets have been studied in recent years, such as sclerostin and receptor activator of NF-kappa B ligand (RANKL). In this review, we first introduce the signaling pathways involved in interactions among osteoblasts, osteoclasts, and osteocytes. Next, we describe clinical trials of denosumab and romosozumab, which are monoclonal antibodies that target RANKL and sclerostin, respectively. We analyze the efficacy of these drugs and provide a profile for the management of osteoporosis.

引用

页码：8758 / 8766

页数：9

共 98 条

[1] Minireview:: Targeting the Wnt/β-catenin pathway to regulate bone formation in the adult skeleton [J].

Baron, Roland ;

Rawadi, Georges .

ENDOCRINOLOGY, 2007, 148 (06) :2635-2643

[2] Fracture Prediction After Discontinuation of 4 to 5 Years of Alendronate Therapy The FLEX Study [J].

Bauer, Douglas C. ;

Schwartz, Ann ;

Palermo, Lisa ;

Cauley, Jane ;

Hochberg, Marc ;

Santora, Art ;

Cummings, Steven R. ;

Black, Dennis M. .

JAMA INTERNAL MEDICINE, 2014, 174 (07) :1126-1134

[3] The effect of a single dose of osteoprotegerin in postmenopausal women [J].

Bekker, PJ ;

Holloway, D ;

Nakanishi, A ;

Arrighi, M ;

Leese, PT ;

Dunstan, CR .

JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 (02) :348-360

[4] A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women [J].

Bekker, PJ ;

Holloway, DL ;

Rasmussen, AS ;

Murphy, R ;

Martin, SW ;

Leese, PT ;

Holmes, GB ;

Dunstan, CR ;

DePaoli, AM .

JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (07) :1059-1066

[5] Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis [J].

Black, Dennis M. ;

Delmas, Pierre D. ;

Eastell, Richard ;

Reid, Ian R. ;

Boonen, Steven ;

Cauley, Jane A. ;

Cosman, Felicia ;

Lakatos, Peter ;

Leung, Ping Chung ;

Man, Zulema ;

Mautalen, Carlos ;

Mesenbrink, Peter ;

Hu, Huilin ;

Caminis, John ;

Tong, Karen ;

Rosario-Jansen, Theresa ;

Krasnow, Joel ;

Hue, Trisha F. ;

Sellmeyer, Deborah ;

Eriksen, Erik Fink ;

Cummings, Steven R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (18) :1809-1822

[6] Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): A randomized trial [J].

Black, Dennis M. ;

Schwartz, Ann V. ;

Ensrud, Kristine E. ;

Cauley, Jane A. ;

Levis, Silvina ;

Quandt, Sara A. ;

Satterfield, Suzanne ;

Wallace, Robert B. ;

Bauer, Douglas C. ;

Palermo, Lisa ;

Wehren, Lois E. ;

Lombardi, Antonio ;

Santora, Arthur C. ;

Cummings, Steven R. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (24) :2927-2938

[7] The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis [J].

Black, DM ;

Greenspan, SL ;

Ensrud, KE ;

Palermo, L ;

McGowan, JA ;

Lang, TF ;

Garnero, P ;

Bouxsein, ML ;

Bilezikian, JP ;

Rosen, CJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (13) :1207-1215

[8] One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis [J].

Black, DM ;

Bilezikian, JP ;

Ensrud, KE ;

Greenspan, SL ;

Palermo, L ;

Hue, T ;

Lang, TF ;

McGowan, JA ;

Rosen, CJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (06) :555-565

[9] Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [J].

Black, DM ;

Cummings, SR ;

Karpf, DB ;

Cauley, JA ;

Thompson, DE ;

Nevitt, MC ;

Bauer, DC ;

Genant, HK ;

Haskell, WL ;

Marcus, R ;

Ott, SM ;

Torner, JC ;

Quandt, SA ;

Reiss, TF ;

Ensrud, KE .

LANCET, 1996, 348 (9041) :1535-1541

[10] 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension [J].

Bone, Henry G. ;

Wagman, Rachel B. ;

Brandi, Maria L. ;

Brown, Jacques P. ;

Chapurlat, Roland ;

Cummings, Steven R. ;

Czerwinski, Edward ;

Fahrleitner-Pammer, Astrid ;

Kendler, David L. ;

Lippuner, Kurt ;

Reginster, Jean-Yves ;

Roux, Christian ;

Malouf, Jorge ;

Bradley, Michelle N. ;

Daizadeh, Nadia S. ;

Wang, Andrea ;

Dakin, Paula ;

Pannacciulli, Nicola ;

Dempster, David W. ;

Papapoulos, Socrates .

LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (07) :513-523

← 1 2 3 4 5 6 7 8 9 10 →